Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $496.49 million
- Book Value:
- Revenue TTM:
- $321.79 million
- Operating Margin TTM:
- Gross Profit TTM:
- $209.58 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Caredx Inc had its IPO on 2014-07-17 under the ticker symbol CDNA.
The company operates in the Healthcare sector and Diagnostics & Research industry. Caredx Inc has a staff strength of 727 employees.
Shares of Caredx Inc opened at $9.42 at the start of the last trading session i.e. 2023-03-22.
The stocks traded within a range of $8.86 - $9.53, and closed at $8.88.
This is a -5.73% slip from the previous day's closing price.
A total volume of 992,120 shares were traded at the close of the day’s session.
In the last one week, shares of Caredx Inc have slipped by -9.76%.
Caredx Inc's Key Ratios
Caredx Inc has a market cap of $496.49 million, indicating a price to book ratio of 1.5754 and a price to sales ratio of 2.0188.
In the last 12-months Caredx Inc’s revenue was $321.79 million with a gross profit of $209.58 million and an EBITDA of $-65636000. The EBITDA ratio measures Caredx Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Caredx Inc’s operating margin was -24% while its return on assets stood at -8.7% with a return of equity of -17.09%.
In Q4, Caredx Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 4%.
Caredx Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.43 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.12. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Caredx Inc’s profitability.
Caredx Inc stock is trading at a EV to sales ratio of 1.3702 and a EV to EBITDA ratio of -7.45. Its price to sales ratio in the trailing 12-months stood at 2.0188.
Caredx Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $542.99 million
- Total Liabilities
- $75.98 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Caredx Inc ended 2023 with $542.99 million in total assets and $0 in total liabilities. Its intangible assets were valued at $542.99 million while shareholder equity stood at $430.91 million.
Caredx Inc ended 2023 with $0 in deferred long-term liabilities, $75.98 million in other current liabilities, 84000.00 in common stock, $-460444000.00 in retained earnings and $37.52 million in goodwill. Its cash balance stood at $89.92 million and cash and short-term investments were $293.09 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Caredx Inc’s total current assets stands at $387.85 million while long-term investments were $0 and short-term investments were $203.17 million. Its net receivables were $66.31 million compared to accounts payable of $9.94 million and inventory worth $19.23 million.
In 2023, Caredx Inc's operating cash flow was $0 while its capital expenditure stood at $177000.
Comparatively, Caredx Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Caredx Inc stock is currently trading at $8.88 per share. It touched a 52-week high of $40.42 and a 52-week low of $40.42. Analysts tracking the stock have a 12-month average target price of $16.33.
Its 50-day moving average was $13.47 and 200-day moving average was $17.22 The short ratio stood at 5.48 indicating a short percent outstanding of 0%.
Around 397.7% of the company’s stock are held by insiders while 10706.9% are held by institutions.
Frequently Asked Questions About Caredx Inc
Similar Industry Stocks (Diagnostics & Research)
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.